NEURON23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. The company was founded in 2018 and is based in San Francisco, California, United States.
NEURON23
Industry:
Health Care Medical Pharmaceutical
Founded:
2018-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.neuron23.com
Total Employee:
11+
Status:
Active
Total Funding:
213.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Current Employees Featured
Founder
Investors List
Surveyor Capital
Surveyor Capital investment in Series C - Neuron23
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - Neuron23
Acorn Bioventures
Acorn Bioventures investment in Series C - Neuron23
Westlake Village BioPartners
Westlake Village BioPartners investment in Series C - Neuron23
SoftBank Vision Fund
SoftBank Vision Fund investment in Series C - Neuron23
Perceptive Advisors
Perceptive Advisors investment in Series C - Neuron23
Redmile Group
Redmile Group investment in Series C - Neuron23
HBM Partners
HBM Partners investment in Series C - Neuron23
Kleiner Perkins
Kleiner Perkins investment in Series C - Neuron23
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Neuron23
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-12 | Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer |
Official Site Inspections
http://www.neuron23.com Semrush global rank: 5.5 M Semrush visits lastest month: 1.55 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neuron23"
Neuron23 - LinkedIn
Neuron23โข Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.See details»
Neuron23 - Crunchbase Company Profile & Funding
Organization. Neuron23 . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Neuron23 is a developer โฆSee details»
Neuron23, Inc. - Drug pipelines, Patents, Clinical trials
May 22, 2025 "Neuron23 is pioneering an entirely new approach to treating genetically defined neurological and immunological diseases and I am thrilled to join the organization at such a pivotal time in its development," said Mr. Yost. โฆSee details»
Neuron23 - Work in biotech
Neuron23 is a biotech company aiming to develop precision medicine for complex neurological and immunological diseases. They are leveraging recent advancements in human genetics to โฆSee details»
Neuron23, Inc. | HBM Partners
Neuron23, Inc., is an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Founded in partnership with Origenis GmbH, Neuron23 is currently โฆSee details»
Neuron23โข Closes $113.5 Million Series A and B โฆ
Dec 16, 2020 Neuron23โข Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent ...See details»
Neuron23โข Closes $113.5 Million Series A and B Financing
Dec 16, 2020 About Neuron23โข Neuron23โข Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and โฆSee details»
Neuron23 - Leadership Team - The Org
The Leadership Team at Neuron23 drives strategic direction and innovation, collaborating across research, translational development, and drug discovery to advance precision medicine โฆSee details»
Neuron23
Neuron23 was founded in late 2018 with the goal of changing the way drugs were discovered and developed for neurodegenerative and immunological diseases, by leveraging data science to โฆSee details»
Neuron23 - VentureRadar
Similar Companies: Envisagenics USA Privately Held Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. The company's mission is to boost the creation of โฆSee details»
Neuron23, Inc. - HBM Healthcare
Neuron23, Inc., is an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Founded in โฆSee details»
Neuron23, Inc. (Neuron23, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅ โฆ
May 22, 2025 About Neuron23 Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological โฆSee details»
Neuron23 Announces $96.5 Million Series D Financing and
22 hours ago Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. โฆSee details»
Neuron23 Announces $96.5 Million Series D Financing and First โฆ
23 hours ago Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. โฆSee details»
Neuron23
In addition to her commitment to Neuron23, Nancy serves as chair of the board of a number of biotechnology companies, including Star Therapeutics, Electra Therapeutics and Latigo โฆSee details»
Neuron23 - Contacts, Employees, Board Members, Advisors
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. โฆSee details»
Neuron23 Announces $96.5 Million Series D Financing and First โฆ
23 hours ago Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinsonโs Disease Business โฆSee details»
Neuron23: Nancy Stagliano, CEO - by Dylan Neel - Biomarker
Jul 21, 2022 In addition to her role at Neuron23, Dr. Stagliano serves as chair of the board of Star Therapeutics, Electra Therapeutics, and Latigo Biosciences. She is active in philanthropy โฆSee details»
Neuron23 doses first subject in trial of NEU-411 for Parkinson's
2 hours ago Neuron23 CEO Nancy Stagliano said: โThe Series D financing represents further endorsement of Neuron23โs industry-leading approach, which leverages state-of-the-art โฆSee details»
Careers - Neuron23
Neuron23 offers a highly competitive total rewards package including a comprehensive set of benefits, generous paid time off, and stock options. Our benefits include: Medical Medical โฆSee details»